These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Studying Pathogenetic Contribution of a Variant of Unknown Significance, p.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells. Pavlova SV; Shulgina AE; Zakian SM; Dementyeva EV Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201382 [TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Mosqueira D; Mannhardt I; Bhagwan JR; Lis-Slimak K; Katili P; Scott E; Hassan M; Prondzynski M; Harmer SC; Tinker A; Smith JGW; Carrier L; Williams PM; Gaffney D; Eschenhagen T; Hansen A; Denning C Eur Heart J; 2018 Nov; 39(43):3879-3892. PubMed ID: 29741611 [TBL] [Abstract][Full Text] [Related]
5. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation. Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154 [TBL] [Abstract][Full Text] [Related]
7. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes. Wang L; Kim K; Parikh S; Cadar AG; Bersell KR; He H; Pinto JR; Kryshtal DO; Knollmann BC J Mol Cell Cardiol; 2018 Jan; 114():320-327. PubMed ID: 29217433 [TBL] [Abstract][Full Text] [Related]
8. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state. Vander Roest AS; Liu C; Morck MM; Kooiker KB; Jung G; Song D; Dawood A; Jhingran A; Pardon G; Ranjbarvaziri S; Fajardo G; Zhao M; Campbell KS; Pruitt BL; Spudich JA; Ruppel KM; Bernstein D Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34117120 [TBL] [Abstract][Full Text] [Related]
9. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction. Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550 [TBL] [Abstract][Full Text] [Related]
10. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations. Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920 [TBL] [Abstract][Full Text] [Related]
11. Incomplete-penetrant hypertrophic cardiomyopathy Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993 [TBL] [Abstract][Full Text] [Related]
12. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells. Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921 [TBL] [Abstract][Full Text] [Related]
13. Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control. Fontaine V; Duboscq-Bidot L; Jouve C; Hamlin M; Curjol A; Briand V; Janiak P; Hulot JS; Pruniaux-Harnist MP; Charron P; Villard E Stem Cell Res; 2021 Apr; 52():102245. PubMed ID: 33610018 [TBL] [Abstract][Full Text] [Related]
14. Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the Bhagwan JR; Collins E; Mosqueira D; Bakar M; Johnson BB; Thompson A; Smith JGW; Denning C F1000Res; 2019; 8():1911. PubMed ID: 32789000 [No Abstract] [Full Text] [Related]
15. Transcriptomic Analysis of Cardiomyocyte Extracellular Vesicles in Hypertrophic Cardiomyopathy Reveals Differential snoRNA Cargo. James V; Nizamudeen ZA; Lea D; Dottorini T; Holmes TL; Johnson BB; Arkill KP; Denning C; Smith JGW Stem Cells Dev; 2021 Dec; 30(24):1215-1227. PubMed ID: 34806414 [TBL] [Abstract][Full Text] [Related]
16. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529 [TBL] [Abstract][Full Text] [Related]